Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...

Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

Gilead Sciences (GILD) stock has drawn the attention of investors with its recent performance over the past month, gaining ...

Gilead Sciences ( ($GILD) ) has provided an update. On November 19, 2025, Gilead Sciences announced that Deborah H. Telman will step down from her ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review ...

Buying $1000 In GILD: If an investor had bought $1000 of GILD stock 5 years ago, it would be worth $2,134.58 today based on a price of $128.61 for GILD at the time of writing.

Deborah Telman is exiting months after the company paid $202 million to settle allegations that it provided illegal kickbacks ...

Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...

Recent analyst updates have led to a slight increase in Gilead Sciences’ fair value price target, moving from $127.23 to $129 ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...

Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...

Around 1,000 doses of Gilead Sciences' HIV prevention drug, lenacapavir, were sent to Zambia and Eswatini under a U.S.